FR2421180A1 - 17-butyrate 21-propionate d'hydrocortisone et son utilisation notamment comme agent anti-inflammatoire - Google Patents

17-butyrate 21-propionate d'hydrocortisone et son utilisation notamment comme agent anti-inflammatoire

Info

Publication number
FR2421180A1
FR2421180A1 FR7907832A FR7907832A FR2421180A1 FR 2421180 A1 FR2421180 A1 FR 2421180A1 FR 7907832 A FR7907832 A FR 7907832A FR 7907832 A FR7907832 A FR 7907832A FR 2421180 A1 FR2421180 A1 FR 2421180A1
Authority
FR
France
Prior art keywords
hydrocortisone
butyrate
propionate
inflammatory agent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7907832A
Other languages
English (en)
Other versions
FR2421180B1 (fr
Inventor
Yasuhide Tachi
Kazuhiko Michishita
Jozi Nakagami
Jiro Sawada
Mitsunori Washitake
Yoshiaki Kamano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of FR2421180A1 publication Critical patent/FR2421180A1/fr
Application granted granted Critical
Publication of FR2421180B1 publication Critical patent/FR2421180B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Dérivé d'hydrocortisone et son utilisation. Ce dérivé d'hydrocortisone est la 17 alpha -butyryloxy-11 beta -hydroxy-21-propionyloxy-4-prégnène-3,20-dione, c'est-à-dire le 17-butyrate 21-propionate d'hydrocortisone; ce composé est préparé en acylant le 17-butyrate d'hydrocortisone avec de l'anhydride d'acide propionique ou un halogénure d'acide propionique. La présente invention est particulièrement utile pour fournir un composé à excellent effet anti-inflammatoire, à excellente absorption percutanée et à moindres effets secondaires.
FR7907832A 1978-03-29 1979-03-28 17-butyrate 21-propionate d'hydrocortisone et son utilisation notamment comme agent anti-inflammatoire Granted FR2421180A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP53036251A JPS6040439B2 (ja) 1978-03-29 1978-03-29 ヒドロコルチゾン誘導体

Publications (2)

Publication Number Publication Date
FR2421180A1 true FR2421180A1 (fr) 1979-10-26
FR2421180B1 FR2421180B1 (fr) 1982-10-22

Family

ID=12464544

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7907832A Granted FR2421180A1 (fr) 1978-03-29 1979-03-28 17-butyrate 21-propionate d'hydrocortisone et son utilisation notamment comme agent anti-inflammatoire

Country Status (11)

Country Link
US (1) US4290962A (fr)
JP (1) JPS6040439B2 (fr)
AR (1) AR221717A1 (fr)
CH (1) CH638227A5 (fr)
DE (1) DE2910899C2 (fr)
FR (1) FR2421180A1 (fr)
GB (1) GB2020291B (fr)
IT (1) IT1116531B (fr)
KE (1) KE3481A (fr)
MY (1) MY8500791A (fr)
SG (1) SG55584G (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2428649A1 (fr) * 1978-06-15 1980-01-11 Beiersdorf Ag Diesters en 17,21 de l'hydrocortisone et medicaments qui en contiennent

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE12237T1 (de) * 1980-12-23 1985-04-15 Schering Ag Neue 6-alpha-methylhydrocortison-derivate, ihre herstellung und verwendung.
DE3133081A1 (de) * 1981-08-18 1983-03-10 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue 6(alpha)-methylprednisolon-derivate, ihre herstellung und verwendung
AT389447B (de) * 1983-01-27 1989-12-11 Taisho Pharmaceutical Co Ltd Verfahren zur herstellung einer topischen steroidsalbe
JPS59137408A (ja) * 1983-01-27 1984-08-07 Taisho Pharmaceut Co Ltd 軟膏
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
AU2004252568B2 (en) 2003-06-27 2011-06-30 Ethicon, Incorporated Regeneration and repair of neural tissue using postpartum-derived cells
US20060223177A1 (en) 2003-06-27 2006-10-05 Ethicon Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
WO2005021515A2 (fr) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase de type iv
WO2005051931A2 (fr) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase
EP1934219A1 (fr) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
CA2626612A1 (fr) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques d'antagonistes du recepteur muscarinique
JP2009512677A (ja) * 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼタイプｉｖ阻害剤の組成物
AU2006325710B2 (en) 2005-12-16 2012-05-17 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
BRPI0717058A2 (pt) * 2006-09-22 2013-10-15 Ranbaxy Lab Ltd Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2008060541A2 (fr) 2006-11-13 2008-05-22 Ethicon, Incorporated Expansion in vitro de cellules post-natales au moyen de microporteurs
EP1958947A1 (fr) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase de type 4
EP2124943A1 (fr) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérases
ES2382715T3 (es) * 2007-03-14 2012-06-12 Ranbaxy Laboratories Limited Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
JP5518893B2 (ja) * 2008-12-19 2014-06-11 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 肺ならびに肺の疾患および障害の治療
CN104356188A (zh) * 2014-10-23 2015-02-18 华中药业股份有限公司 一种丁酸氢化可的松的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2144405A1 (de) * 1971-09-04 1973-03-08 Merck Patent Gmbh Verfahren zur herstellung von estern der pregnanreihe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195748B (de) * 1961-06-24 1965-07-01 Vismara Francesco Spa Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden
GB1043347A (en) * 1963-05-10 1966-09-21 Glaxo Lab Ltd 17,21-orthoesters of steroids
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
US3422193A (en) * 1966-08-11 1969-01-14 Schering Corp 17-mono esters of corticoids
DE2826257C3 (de) * 1978-06-15 1980-12-04 Beiersdorf Ag, 2000 Hamburg Hydrocortison-17,21-diester und Verfahren zu deren Herstellung, diese enthaltende Arzneimittel sowie Hydrocortison -17-propionat als Zwischenprodukt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2144405A1 (de) * 1971-09-04 1973-03-08 Merck Patent Gmbh Verfahren zur herstellung von estern der pregnanreihe

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2428649A1 (fr) * 1978-06-15 1980-01-11 Beiersdorf Ag Diesters en 17,21 de l'hydrocortisone et medicaments qui en contiennent

Also Published As

Publication number Publication date
KE3481A (en) 1985-01-04
IT1116531B (it) 1986-02-10
GB2020291A (en) 1979-11-14
GB2020291B (en) 1982-10-06
AR221717A1 (es) 1981-03-13
SG55584G (en) 1985-03-08
IT7948501A0 (it) 1979-03-27
DE2910899C2 (de) 1986-02-13
DE2910899A1 (de) 1979-10-11
JPS54128560A (en) 1979-10-05
MY8500791A (en) 1985-12-31
US4290962A (en) 1981-09-22
JPS6040439B2 (ja) 1985-09-11
FR2421180B1 (fr) 1982-10-22
CH638227A5 (fr) 1983-09-15

Similar Documents

Publication Publication Date Title
FR2421180A1 (fr) 17-butyrate 21-propionate d'hydrocortisone et son utilisation notamment comme agent anti-inflammatoire
EP0129283A3 (fr) Compositions pharmaceutiques topiques à pénétration améliorée contenant des corticostéroides
NO166152C (no) Skjoeteanordning for sammenfoeyning av to kabelender, samt fremgangsmaate for sammenstilling av saadan anordning.
AU509635B2 (en) Improved ointment containing esters of betamethasone
ES8504450A1 (es) Un procedimiento para preparar una crema del tipo aceite en agua a base de butirato-propionato de hidrocortisona
JPS5366442A (en) Antitumors
AU5034879A (en) Acid addition salt of 2beta,16beta diperidino 5 alpha androstane derivatives
NL7706709A (nl) Werkwijze voor de bereiding van perfluoralkoxy- propionzuurfluoriden.
AU4999579A (en) Pipe or cable clip
ES8203850A1 (es) Un procedimiento para preparar la sal del acido (1-bencil- 1h-indazol-3-il)oxi acetico con lisina
NL7805803A (nl) Azimuth-correctie van kopspleten.
JPS51145538A (en) Anti-corrosive tape for wire-cable or pipe covering
IT7820313A0 (it) Procedimento per la preparazione di acido monocloroacetico da acido acetico e cloro elementare.
DK312483A (da) Kortikoidholdige praeparater til topisk applikation
BE876073A (fr) Fenetre pour caravanes camping-cars ou similaires
JPS54119691A (en) Jumper wire
IE45634L (en) Prostane derivatives
SU724561A1 (ru) Антистатическа добавка к мазуту
IE42283L (en) 6-fluoro-16-methyl-pregna-1,4,8-triene-3,20-diones
SU605587A1 (ru) Способ борьбы с цитоспорозом блони
GB1202001A (en) 6alpha,9alpha-DIFLUOROPREDNISOLONE 17,21-DIESTERS
GB1273955A (en) Dexamethasone-17-valerate and processes for preparing it
IE35822L (en) 6ó, 16ó-dimethylsteroids.
SE7505340L (sv) Forbettringar av och med avseende pa "strapdown" troghetsnavigeringssystem.
IT7905211A0 (it) Perfezionamenti al differenziale di autoveicoli.